David O. Watson Sells 2,201 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 2,201 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $65,941.96. Following the sale, the general counsel now owns 105,555 shares in the company, valued at approximately $3,162,427.80. This represents a 2.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Apellis Pharmaceuticals Stock Up 0.9 %

Shares of APLS opened at $30.39 on Thursday. The business’s fifty day moving average price is $31.95 and its two-hundred day moving average price is $33.25. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -14.97 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.17) EPS. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective for the company. in a report on Tuesday, December 17th. Royal Bank of Canada reissued a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday. Robert W. Baird lowered their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 14th. Finally, Citigroup dropped their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Envestnet Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after buying an additional 39,931 shares during the period. JPMorgan Chase & Co. raised its position in shares of Apellis Pharmaceuticals by 23.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after acquiring an additional 735,160 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Apellis Pharmaceuticals by 90.7% in the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after purchasing an additional 20,435 shares during the period. Algert Global LLC boosted its position in shares of Apellis Pharmaceuticals by 137.8% in the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock worth $4,742,000 after purchasing an additional 71,650 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Apellis Pharmaceuticals in the 3rd quarter worth $1,370,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).